Blood cancers

Long-term benefits seen with ibrutinib in CLL/SLL: RESONATE

Extended ibrutinib treatment showed sustained efficacy in patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma, six-year results from the RESONATE trial shows. Presenting the findings at Blood 2019 during the HSANZ free communications CLL session, Professor Stephen Mulligan, a co-investigator and haematologist at the Royal North Shore Hospital in Sydney, said the ...

Already a member?

Login to keep reading.

© 2021 the limbic